Full Text View
Tabular View
Study Results
Related Studies
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
This study has been completed.
Study NCT00183248   Information provided by University of Miami

First Received on September 11, 2005.   Last Updated on September 17, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Transplantation
Kidney Disease
Kidney Failure
Additional conditions recognized in this trial
Kidney Diseases
Renal Insufficiency
More general conditions related to this trial
Urologic Diseases
Interventions listed in this trial
Alemtuzumab
Mycophenolate mofetil
Sirolimus
Tacrolimus
Kidney transplant
Additional drug interventions recognized in this trial
Campath 1G
Mycophenolic Acid
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Miami
Immune Tolerance Network (ITN)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services